Equity Details
Price & Market Data
Price: $5.76
Daily Change: -$0.36 / 6.25%
Daily Range: $5.68 - $6.20
Market Cap: $447,573,280
Daily Volume: 1,022,835
Performance Metrics
1 Week: -4.36%
1 Month: -10.66%
3 Months: -19.03%
6 Months: -30.40%
1 Year: 116.7%
YTD: -42.60%
About Lexeo Therapeutics, Inc. (LXEO)
Full market details for Lexeo Therapeutics, Inc. (LXEO). Current price: 5.76, daily change: -$0.36 / 6.25%. Market cap: 447,573,280. Comprehensive performance data across all periods.
Company Details
Employees: 59
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.